<< Back
BusinessWeek Report Lists Cepheid as Winner of 2006 Industrial Design Excellence Award for Reagent Bead Dispenser

Dispenser Dramatically Improves Handling of Reagent Beads and Increases Lab Efficiency

SUNNYVALE, Calif., July 5 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD), today announced its receipt of a 2006 Silver Industrial Design Excellence Award (IDEA) for the Cepheid Reagent Bead Dispenser. The BusinessWeek IDEA report hit newsstands on June 30th with an in-depth analysis of the winners. IDSA's quarterly magazine, Innovation, will publish information on the Gold, Bronze and Silver winners in its annual Yearbook this Fall.

The Cepheid Dispenser is a low-cost, disposable storage and delivery vehicle for Cepheid's Reagent Beads. Heretofore the 2.6mm beads have been shipped in test tubes, and then handled with tweezers. The Reagent Bead Dispenser adds a new level of convenience to the handling of Cepheid's already easy-to-use beaded reagent mixes where users are required to add only molecular grade water to reconstitute the complex mixtures. The unique bead dispenser complements Cepheid's existing line of products that simplify lab test procedures and produce test results quickly and accurately. Cepheid plans to package all reagent beads in the award-winning dispensers, including SmartMix(TM) and the full menu of Analyte Specific Reagent products.

"We are honored to be recognized by the Industrial Designers Society of America for our Reagent Bead Dispenser," said Cepheid Chief Executive Officer John Bishop. "The dispenser is yet another product from Cepheid designed to reduce manual steps and risk of error. We have received positive feedback from scientists and researchers regarding its ease-of-use."

A jury of 18 leading thinkers in the design world, led by Jury Chair Chris Conley, spent many days previewing entries online and two days of intense, face-to-face evaluation and debate on IDEA, one of the world's most prestigious design competitions. Judging criteria for each entry focused on five areas of industrial design excellence: design innovation, benefit to the user, benefit to the client/business, ecological responsibility, and appropriate aesthetics and appeal.

"With the rapid changes occurring in technology, commerce and society, it takes real leadership to define meaningful new products and services and deliver them to the market," said Conley, IDSA, co-founder and director of Chicago-based consulting firm Gravity Tank. "Consumers expect new products and services to not only serve their needs, but to delight them. The 2006 IDEA winners represent the best of global product design and the best people and firms working to realize design's potential in everyday life."

The jury awarded 27 entries the coveted Gold award, while 39 entries received Silver awards and 42 won Bronze awards. IDEA is co-sponsored by BusinessWeek and the Industrial Designers Society of America (IDSA).

About IDEA, Industrial Designers and IDSA

The IDEA program fosters business and public understanding about the impact of industrial design excellence on the quality of life and the economy. Industrial designers determine the form, use features and interaction qualities of manufactured products, packaging and digital media systems. They study people at work, at home and in motion to create satisfying experiences with products from the kitchen and the office to the hospital and the warehouse, shaping these to fit their customers and to make effective use of industrial processes. In this way, industrial designers have a quiet but profound presence in almost everything people encounter during the day. IDSA is the voice of industrial design, committed to advancing the profession through education, information, community and advocacy. Visit www.idsa.org for more information.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, California, is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance, and demand for products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the potential for lengthy sales cycles in certain markets; the performance and market acceptance of new products; sufficient customer demand; the occurrence of unforeseen problems with respect to the product; the impact of competitive products and pricing; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2005 and its other reports filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    At the Company:
    John L. Bishop                      John R. Sluis
    CEO, Cepheid                        CFO, Cepheid
    408-541-4191                        408-541-4191
    john.bishop@cepheid.com             john.sluis@cepheid.com

    At Financial Relations Board:       At Schwartz Communications:
    Tricia Ross                         Chris Stamm, Nigel Smith
    Investor/Analyst Information        781-684-0770
    617-520-7064                        cepheid@schwartz-pr.com

SOURCE Cepheid
CONTACT: John L. Bishop, CEO, john.bishop@cepheid.com, or John R. Sluis,
CFO, john.sluis@cepheid.com, both of Cepheid, +1-408-541-4191; or
Investor/Analyst Information, Tricia Ross of Financial Relations Board,
+1-617-520-7064, tross@financialrelationsboard.com, for Cepheid; or Chris
Stamm, or Nigel Smith, both of Schwartz Communications, +1-781-684-0770,
cepheid@schwartz-pr.com, for Cepheid
Web site: http://www.idsa.org
Web site: http://www.cepheid.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Cepheid's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.